ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

Search

Advanced Search

vaccineSubscribe to vaccine

Pandemic and the Patent System

Vol. 56, Issue No. 44, 30 Oct, 2021
C Niranjan Rao

This article discusses the patent system in the context of the current pandemic. It suggests that the Trade-Related Aspects of Intellectual Property Rights Agreement and the TRIPS-compliant Indian Patent Law could be used to either grant compulsory licences or they could go by the provision that allows the government to use the patent. The road block seems to be the technological capabilities than the patent system itself.

Export-induced Loss in Employment and Earnings during the First Year of the COVID-19 Pandemic

Vol. 56, Issue No. 41, 09 Oct, 2021
Amit Sadhukhan, Sahana Roy Chowdhury

The COVID-19 pandemic has been an unprecedented exogenous shock in the world economy unlike the global financial crisis in 2008, which was endogenously determined in the structure of capitalist financial market. Given the fact that Indian export sector significantly contributes to the Indian economy in general and employment in particular, it is worth examining how the Indian gross domestic product and exports changed in comparison with the world GDP and world exports respectively, in the first year of the COVID-19 pandemic in 2020–21 vis-à-vis the GFC in 2008. Which industries are affected the most, in terms of export loss, during this COVID-19 crisis? What have been the consequences of these falling export on employment and earnings in the Indian export sector? This study estimates that in the COVID-19 year 2020–21, Indian exports have fallen by `3.74 lakh crore, with a plausible loss of direct employment by 5.06 lakh and an estimated loss of earnings around `12.4 thousand crore across 85 commodities.

 

The Pandemic and Its Discontents in India

Vol. 56, Issue No. 41, 09 Oct, 2021
Sylvia Karpagam

India and the Pandemic: The First Year, Essays from The India Forum by The India Forum, 2021; Hyderabad: Orient Blackswan; pp xvii + 335, `695.

 

Covid-19 Pandemic: Shortages, Hesitancy and Pricing Plague India’s Covid-19 Vaccination Programme

India’s COVID-19 vaccination roll-out has been marred by challenges of shortages and hesitancy. With the new open market policy of vaccine procurement and possible entry of foreign-made vaccines, government responsibility and transparency are the need of the hour.

COVID-19 and Tribal Communities: How State Neglect Increased Marginalisation during the Pandemic

In the absence of state support and social security, the COVID-19 pandemic and lockdowns created short- and long-term hardships for already marginalised tribal communities in India.

COVID-19 Vaccine Accessibility

Vol. 56, Issue No. 26-27, 26 Jun, 2021
Amarjit Bhullar

The patent waiver procedure at the World Trade Organization needs to be fast-tracked. The global community must not be constrained by the interests of private industry and saving lives is what matters.

 

Why India’s Vaccine Companies Are Profiteering in the Pandemic

Vol. 56, Issue No. 22, 29 May, 2021
Sandhya Srinivasan, Mohan Rao

The crisis of COVID-19 vaccines in India is a consequence of government policies dating back decades. Private foundations led by the Bill and Melinda Gates Foundation have engineered a shift in research and manufacture of essential technologies such as vaccines to private biotech labs and factories. Companies such as the Serum Institute of India and Bharat Biotech can dictate terms and prices of vaccines developed with public support because the closure of public vaccine manufacturing units over a decade ago has left the government at the mercy of the private sector.

 

Of Vaccine Shortages and Transparency

Vol. 56, Issue No. 16, 17 Apr, 2021

The government’s narrative on vaccination should reflect sincerity, truth and transparency.

 

The Interconnectedness Of Illegal Wildlife Trade and COVID-19: An Infographic

Emergency Use Authorisation of COVID-19 Vaccines

Vol. 55, Issue No. 51, 26 Dec, 2020

In granting EUA to vaccines, both urgency and adherence to protocol should be taken into consideration.

 

Exiting the Lockdown Sustainably

Vol. 55, Issue No. 24, 13 Jun, 2020
Avinash Persaud

.

Process of a Vaccine Trial

Vol. 35, Issue No. 08-09, 19 Feb, 2000
Mukul Kumar, Surabhi Tandon

This paper describes the complex process of a clinical trial of Mw anti-leprosy vaccine. The receivers of the bio-medical products are viewed not as mere cases seen through the protocol of the trial but as persons within different social contexts with their own understanding of the product in relation to their bodies. The issue becomes more complex in the case of the Mw vaccine as it is not only a prophylactic but also a therapeutic vaccine the patients negotiate between their understanding of the disease and the product. This also influences the biomedical discourse as the clinicians have to negotiate a balance between the therapeutic and experimental aspects of their work.

Back to Top

EPW

Term & Policy

Circulation

Advertisement

Connect with us